Since innate immune cells can contribute to tumor suppression boosting a strong adaptive immune response, we hypothesized that infiltration on M1 macrophages in the TME by BRAF/VEGFA targeting would enhance the efficacy of the ICB, which primarily unleashes anticancer T‐cell response. The gene discussed is BRAF; the disease is neoplasm.